Shares of Idorsia Ltd (OTCMKTS:IDRSF) have been given a consensus rating of “Buy” by the seven ratings firms that are currently covering the stock, MarketBeat reports. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company.
A number of brokerages have weighed in on IDRSF. Barclays reissued an “overweight” rating on shares of Idorsia in a report on Monday, July 19th. Jefferies Financial Group raised shares of Idorsia from a “hold” rating to a “buy” rating in a report on Thursday, September 16th. Credit Suisse Group reiterated an “outperform” rating on shares of Idorsia in a research report on Tuesday, July 6th. Morgan Stanley restated an “equal weight” rating on shares of Idorsia in a research report on Tuesday. Finally, JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Idorsia in a report on Wednesday, July 28th.
Shares of IDRSF opened at $22.80 on Monday. Idorsia has a 52 week low of $22.68 and a 52 week high of $33.25. The stock has a 50 day moving average of $23.99 and a 200-day moving average of $25.91.
Idorsia Ltd. operates as a biopharmaceutical firm which focuses on discovery, development and commercialization of innovative medicines for unmet medical needs. The firm targets patients who are suffering with Fabry disease, insomnia, Cerebral vasospasm associated with aSAH and systemic lupus erythematosus.
Further Reading: How does equity income fit into an investing strategy?
Receive News & Ratings for Idorsia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Idorsia and related companies with MarketBeat.com's FREE daily email newsletter.